메뉴 건너뛰기




Volumn 21, Issue 6, 2019, Pages 1299-1304

Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States

Author keywords

CVOTs; dulaglutide; GLP 1 receptor agonist; type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; ANTIDIABETIC AGENT; DULAGLUTIDE; FUSION PROTEIN; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT;

EID: 85062789466     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13649     Document Type: Article
Times cited : (36)

References (27)
  • 1
    • 85039751538 scopus 로고    scopus 로고
    • 9. Cardiovascular disease and risk management: standards of medical care in diabetes—2018
    • American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(suppl 1):S86-S104.
    • (2018) Diabetes Care , vol.41 , pp. S86-S104
  • 2
    • 85062798455 scopus 로고    scopus 로고
    • Guidance For Industry Diabetes Mellitus - Evaluating Cardiovascular Risk In New Antidiabetic Therapies To Treat Type 2 Diabetes., Accessed November 15
    • U.S. Food and Drug Administration. Guidance For Industry: Diabetes Mellitus - Evaluating Cardiovascular Risk In New Antidiabetic Therapies To Treat Type 2 Diabetes. https://www.fda.gov/downloads/Drugs/Guidances/ucm071627.pdf. Accessed November 15, 2018.
    • (2018)
  • 3
    • 85019567375 scopus 로고    scopus 로고
    • More than 7 years of hindsight: revisiting the FDA's 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications
    • Regier EE, Venkat MV, Close KL. More than 7 years of hindsight: revisiting the FDA's 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications. Clin Diabetes. 2016;34:173-180.
    • (2016) Clin Diabetes , vol.34 , pp. 173-180
    • Regier, E.E.1    Venkat, M.V.2    Close, K.L.3
  • 4
    • 85038951494 scopus 로고    scopus 로고
    • Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors' expert forum
    • Cefalu WT, Kaul S, Gerstein HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors' expert forum. Diabetes Care. 2018;41:14-31.
    • (2018) Diabetes Care , vol.41 , pp. 14-31
    • Cefalu, W.T.1    Kaul, S.2    Gerstein, H.C.3
  • 5
    • 85062771238 scopus 로고    scopus 로고
    • To_Data. IQVIA Real-World Data Adjudicated Claims., Accessed November 15
    • B.R.I.D.G.E To_Data. IQVIA Real-World Data Adjudicated Claims. https://www.bridgetodata.org/node/824. Accessed November 15, 2018.
    • (2018)
  • 6
    • 85062778134 scopus 로고    scopus 로고
    • Facts for Features Older Americans Month May 2017, Accessed November 15
    • United States Census Bureau. Facts for Features: Older Americans Month: May 2017 https://www.census.gov/newsroom/facts-for-features/2017/cb17-ff08.html. Accessed November 15, 2018.
    • (2018)
  • 7
    • 85062800304 scopus 로고    scopus 로고
    • National Health and Nutrition Examination Survey., Accessed November 15
    • Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. https://www.cdc.gov/nchs/nhanes/index.htm. Accessed November 15, 2018.
    • (2018)
  • 8
    • 85018965453 scopus 로고    scopus 로고
    • Type 2 diabetes mellitus unawareness, prevalence, trends and risk factors: National Health and Nutrition Examination Survey (NHANES) 1999-2010
    • Zhang N, Yang X, Zhu X, Zhao B, Huang T, Ji Q. Type 2 diabetes mellitus unawareness, prevalence, trends and risk factors: National Health and Nutrition Examination Survey (NHANES) 1999-2010. J Int Med Res. 2017;45:594-609.
    • (2017) J Int Med Res , vol.45 , pp. 594-609
    • Zhang, N.1    Yang, X.2    Zhu, X.3    Zhao, B.4    Huang, T.5    Ji, Q.6
  • 9
    • 85065680992 scopus 로고    scopus 로고
    • Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population
    • Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. Am J Manag Care. 2018;24(suppl 8):S146-S155.
    • (2018) Am J Manag Care , vol.24 , pp. S146-S155
    • Wittbrodt, E.T.1    Eudicone, J.M.2    Bell, K.F.3    Enhoffer, D.M.4    Latham, K.5    Green, J.B.6
  • 10
    • 85011676254 scopus 로고    scopus 로고
    • Trends in dietary intake among adults with type 2 diabetes: NHANES 1988-2012
    • Casagrande SS, Cowie CC. Trends in dietary intake among adults with type 2 diabetes: NHANES 1988-2012. J Hum Nutr Diet. 2017;30:479-489.
    • (2017) J Hum Nutr Diet , vol.30 , pp. 479-489
    • Casagrande, S.S.1    Cowie, C.C.2
  • 11
    • 85062800063 scopus 로고    scopus 로고
    • Overview of NHANES Survey Design and Weights., Accessed November 15
    • Centers for Disease Control and Prevention. Overview of NHANES Survey Design and Weights. https://www.cdc.gov/nchs/tutorials/environmental/orientation/sample_design/. Accessed November 15, 2018.
    • (2018)
  • 12
    • 85062776092 scopus 로고    scopus 로고
    • Accessed November 15,, https://clinicaltrials.gov
    • U.S. National Library of Medicine. ClinicalTrialsgov https://clinicaltrials.gov. Accessed November 15, 2018.
    • (2018)
  • 13
    • 27144439138 scopus 로고    scopus 로고
    • Standard deviations and standard errors
    • Altman DG, Bland JM. Standard deviations and standard errors. BMJ. 2005;331:903.
    • (2005) BMJ , vol.331 , pp. 903
    • Altman, D.G.1    Bland, J.M.2
  • 14
    • 85023614886 scopus 로고    scopus 로고
    • Design and baseline characteristics of participants in the researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
    • Gerstein HC, Colhoun HM, Dagenais GR, et al. Design and baseline characteristics of participants in the researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20:42-49.
    • (2018) Diabetes Obes Metab , vol.20 , pp. 42-49
    • Gerstein, H.C.1    Colhoun, H.M.2    Dagenais, G.R.3
  • 15
    • 85030448557 scopus 로고    scopus 로고
    • Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
    • Protocol for
    • Protocol for:Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228-1239.
    • (2017) N Engl J Med , vol.377 , pp. 1228-1239
    • Holman, R.R.1    Bethel, M.A.2    Mentz, R.J.3
  • 16
    • 84978839381 scopus 로고    scopus 로고
    • Liraglutide and cardiovascular outcomes in type 2 diabetes
    • Protocol for
    • Protocol for:Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med. 2016;375:311-322.
    • (2016) New Engl J Med. , vol.375 , pp. 311-322
    • Marso, S.P.1    Daniels, G.H.2    Brown-Frandsen, K.3
  • 17
    • 84994813253 scopus 로고    scopus 로고
    • Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
    • Supplement to
    • Supplement to:Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.
    • (2016) N Engl J Med , vol.375 , pp. 1834-1844
    • Marso, S.P.1    Bain, S.C.2    Consoli, A.3
  • 18
    • 84977480444 scopus 로고    scopus 로고
    • Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial
    • Holman RR, Bethel MA, George J, et al. Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial. Am Heart J. 2016;174:103-110.
    • (2016) Am Heart J , vol.174 , pp. 103-110
    • Holman, R.R.1    Bethel, M.A.2    George, J.3
  • 19
    • 84978839381 scopus 로고    scopus 로고
    • Liraglutide and cardiovascular outcomes in type 2 diabetes
    • Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med. 2016;375:311-322.
    • (2016) New Engl J Med. , vol.375 , pp. 311-322
    • Marso, S.P.1    Daniels, G.H.2    Brown-Frandsen, K.3
  • 20
    • 84994813253 scopus 로고    scopus 로고
    • Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
    • Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.
    • (2016) N Engl J Med , vol.375 , pp. 1834-1844
    • Marso, S.P.1    Bain, S.C.2    Consoli, A.3
  • 21
    • 84929289581 scopus 로고    scopus 로고
    • Rationale, design, and baseline characteristics in evaluation of LIXisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
    • Bentley-Lewis R, Aguilar D, Riddle MC, et al. Rationale, design, and baseline characteristics in evaluation of LIXisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015;169:631-638.
    • (2015) Am Heart J , vol.169 , pp. 631-638
    • Bentley-Lewis, R.1    Aguilar, D.2    Riddle, M.C.3
  • 22
    • 85062767211 scopus 로고    scopus 로고
    • FDA Drug Shortages., Accessed November 15
    • U.S. Food & Drug Administration. FDA Drug Shortages. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Albiglutide+%28Tanzeum%29+Injection&st=d&tab=tabs-2. Accessed November 15, 2018.
    • (2018)
  • 23
    • 85013287694 scopus 로고    scopus 로고
    • Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
    • Mentz RJ, Bethel MA, Gustavson S, et al. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Am Heart J. 2017;187:1-9.
    • (2017) Am Heart J , vol.187 , pp. 1-9
    • Mentz, R.J.1    Bethel, M.A.2    Gustavson, S.3
  • 24
    • 84978839381 scopus 로고    scopus 로고
    • Liraglutide and cardiovascular outcomes in type 2 diabetes
    • Supplement to
    • Supplement to:Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New Engl J Med. 2016;375:311-322.
    • (2016) New Engl J Med , vol.375 , pp. 311-322
    • Marso, S.P.1    Daniels, G.H.2    Brown-Frandsen, K.3
  • 25
    • 84926434654 scopus 로고    scopus 로고
    • Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
    • Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
    • (2014) BMC Med Res Methodol , vol.14 , pp. 135
    • Wan, X.1    Wang, W.2    Liu, J.3    Tong, T.4
  • 26
    • 85060179761 scopus 로고    scopus 로고
    • A data-zone scoring system to assess the generalizability of clinical trial results to individual patients
    • [published online ahead of print November 26, 2018]., [Epub ahead of print]
    • Laffin LJ, Besser SA, Alenqhat FJ. A data-zone scoring system to assess the generalizability of clinical trial results to individual patients [published online ahead of print November 26, 2018]. Eur J Prev Cardiol. 2018. https://doi.org/10.1177/2047487318815967. [Epub ahead of print].
    • (2018) Eur J Prev Cardiol
    • Laffin, L.J.1    Besser, S.A.2    Alenqhat, F.J.3
  • 27
    • 85009179196 scopus 로고    scopus 로고
    • Computer-aided assessment of the generalizability of clinical trial results
    • Cahan A, Cahn S, Cimino JJ. Computer-aided assessment of the generalizability of clinical trial results. Int J Med Inform. 2017;99:60-66.
    • (2017) Int J Med Inform , vol.99 , pp. 60-66
    • Cahan, A.1    Cahn, S.2    Cimino, J.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.